Encefalopatia hepática
Revisado por Dr Toni Hazell, FRCGPÚltima atualização por Dr Philippa Vincent, MRCGPÚltima atualização 10 Sept 2026
Atende aos diretrizes editoriais
- BaixarBaixar
- Compartilhar
- Language
- Discussão
- Ask Patient
- Versão em Áudio
- Adicionar às fontes preferidas no Google
Profissionais de Saúde
Os artigos de Referência Profissional são projetados para uso por profissionais de saúde. Eles são escritos por médicos do Reino Unido e baseados em evidências de pesquisa, diretrizes do Reino Unido e da Europa. Você pode encontrar o Insuficiência hepática artigo mais útil, ou um dos nossos outros artigos de saúde.
Veja também o separado Insuficiência hepática, Cirrose e Síndrome hepatorrenal artigos.
O que é encefalopatia hepática?
Hepatic encephalopathy is defined as a spectrum of neuropsychiatric abnormalities in patients with liver failure, after exclusion of other known brain disease. Hepatic encephalopathy causes a range of symptoms from subtle cognitive changes to severe confusion, personality alterations, disorientation, lethargy, and coma.1
Hepatic encephalopathy is thought to be caused by the accumulation of neurotoxins in patients with liver dysfunction.1
Epidemiologia
Studies suggest that hepatic encephalopathy is diagnosed in between 44 and 51% of people with cirrhosis. However, it is thought that up to 80% of people with cirrhosis may have hepatic encephalopathy with more subtle symptoms.1
Causes of hepatic encephalopathy
Hepatic encephalopathy can arise directly from chronic liver disease or from portosystemic shunts where the portal circulation is redirected into the systemic circulation, bypassing the liver and therefore causing a build-up of toxic metabolites.1 Ammonia is the main toxin causing hepatic encephalopathy; other factors include high levels of bile acids in the CSF, manganese accumulation in the basal ganglia, and oxidative stress. Hepatic encephalopathy causes brain cell destruction but brain cell destruction is also one of the underlying mechanisms that causes hepatic encephalopathy - inflammation, in the presence of cirrhosis, appears to lead to tumour necrosis factor (TNF) production which contributes to hepatic encephalopathy development.2
Causes of liver failure include:
Acute liver failure:
Hepatite viral.
Paracetamol overdose.
Ischaemia eg following sepsis.
Chronic liver failure (cirrhosis):
Alcohol overuse.
Chronic viral hepatitis.
Non-alcoholic fatty liver disease.
In cirrhosis, hepatic encephalopathy is often triggered by a specific precipitant including:
Lesão renal aguda.
Desequilíbrio eletrolítico.
Hemorragia gastrointestinal.
Infecção.
Constipação.
Medicamentos sedativos - por exemplo, opiáceos, benzodiazepinas, antidepressivos e antipsicóticos.
Diuréticos.
Sintomas de encefalopatia hepática (apresentação)
Symptoms include cognitive changes, personality alterations, disorientation, lethargy, and coma. Extrapyramidal signs associated with HE have been clearly documented - these can be episodic and associated with bouts of hepatic encephalopathy; however, they can also be progressive and appear more similar to Parkinson's disease.3
Grading of hepatic encephalopathy - West Haven Criteria1
The West Haven criteria have become the standard criteria to assist in the diagnosis of hepatic encephalopathy:
Grau 0
Minimal hepatic encephalopathy.
Grau 1
Falta de consciência trivial.
Euforia ou ansiedade.
Redução da capacidade de concentração; desempenho prejudicado em adição ou subtração.
Grau 2
Letargia ou apatia.
Desorientação mínima em relação ao tempo ou lugar.
Mudança sutil de personalidade.
Comportamento inadequado.
Grau 3
Sonolência a semi-estupor, mas responsivo a estímulos verbais.
Confusão.
Desorientação grave.
Grau 4
Coma.
Grading of hepatic encephalopathy - World Health Congress of Gastroenterology criteria
The World Health Congress of Gastroenterology criteria categorise hepatic encephalopathy based on its underlying aetiology: offering a comprehensive approach to the management of hepatic encephalopathy.
Type A (acute): Hepatic encephalopathy associated with acute liver failure, typically with cerebral oedema.
Type B (bypass): Hepatic encephalopathy caused by portal-systemic shunting, without associated intrinsic liver disease.
Type C (cirrhosis): Hepatic encephalopathy in patients with cirrhosis, which is further subdivided into episodic, persistent, and minimal encephalopathy.
Grading of hepatic encephalopathy - covert vs overt
There can be challenges in diagnosing subtle changes in early very mild hepatic encephalopathy. The term covert hepatic encephalopathy can be used to describe minimal hepatic encephalopathy including grades 0 and 1 in the West Haven criteria.
Investigações14
LFTs and renal function.
Testes psicométricos - estão se tornando cada vez mais úteis no diagnóstico de encefalopatia hepática mínima.
Os níveis de amônia arterial ou sérica estão elevados e podem ajudar no diagnóstico.
Eletroencefalograma (EEG): pode mostrar ondas de alta amplitude e baixa frequência e ondas trifásicas, mas esses achados não são específicos para encefalopatia hepática.
A ressonância magnética/tomografia computadorizada pode ajudar a excluir outras causas de alteração da função mental, como lesões intracranianas.
As respostas evocadas visuais mostram padrões clássicos associados à encefalopatia hepática.
Diagnóstico diferencial1
Outras causas de encefalopatia, incluindo:
Intracranial lesions - eg, hemorragia, evento cerebrovascular, tumor.
Infection - eg, meningite, encefalite, abscesso intracraniano.
Metabolic - eg, hipoglicemia, electrolyte imbalance, anoxia, lesão renal aguda.
Outras causas de hiperamonemia - por exemplo, ureterosigmoidostomia, distúrbios hereditários do ciclo da ureia.
Toxic - eg, abuso de substâncias, problemas relacionados ao álcool.
Medicamentos - por exemplo, hipnóticos sedativos, antidepressivos, agentes antipsicóticos e salicilatos.
Pós-convulsão.
Tratamento e manejo da encefalopatia hepática156
Management usually involves ammonia lowering and supportive care.
Methods to combat raised levels of ammonia include lactulose/lactitol and rifaximin.
L-Ornithine L-Aspartate (LOLA) is a drug that can reduce ammonia and has been shown to be beneficial. 2
Trials of other drugs have not shown significant benefit in studies, although further studies are taking place.7
Nutritional support, including regular small meals. Fasting should be avoided. Restriction of protein intake was once thought to be beneficial, but this was not supported by further evidence. Adequate nutrition is essential; in cirrhosis, there is actually an increased requirement for protein.8Some patients experience worsening of their symptoms with meat intake - vegetable proteins are a useful alternative.1
Good hydration and electrolyte correction.
Sedative drugs should be avoided wherever possible. If patients are agitated then a safe environment and restraint is often preferable to sedation.
Other than ammonia-increasing medication, there is no evidence of benefit from other drug treatments.
Surgical procedures to close portosystemic shunts can be effective where the hepatic encephalopathy is caused by a shunt and is not responding to supportive management.
Transplante de fígado may be offered; where liver transplantation occurs, reversal of the cognitive effects of hepatic encephalopathy may be seen within 5 years.1
Prognóstico da encefalopatia hepática
Patients with cirrhosis and hepatic encephalopathy have a risk of recurrence. Neurological deficits may persist despite an apparent return to normality; these deficits tend to be worse in patients who have had multiple episodes of hepatic encephalopathy.1
A single episode of overt hepatic encephalopathy increases mortality risk independently of other organ failures. The prognosis tends to be worse in hepatic encephalopathy associated with liver failure. Studies have shown a 44% survival at 12 months and 35%1 survival at 24 months in those needing hospitalisation for their hepatic encephalopathy.
It is advised that all patients with a history of overt hepatic encephalopathy or with minimal hepatic encephalopathy avoid driving.1
Prevenção
Rifaximin is recommended by the National Institute for Health and Care Excellence (NICE) as an option for reducing the recurrence of episodes of overt hepatic encephalopathy in people aged 18 years or older.9
Lactulose is recommended for all patients with cirrhosis after a single episode of hepatic encephalopathy.1
Patients should adhere to a regulated diet, high in protein, and avoid long periods of fasting. A bedtime snack is often recommended. 1
Atualizações exclusivas para profissionais de saúde
Mantenha-se informado com as últimas atualizações clínicas, insights profissionais e orientações baseadas em evidências. O boletim informativo Patient Pro seleciona conteúdo essencial para profissionais de saúde—entregue diretamente na sua caixa de entrada.
Ao se inscrever, você aceita nossos Política de Privacidade. Você pode cancelar a inscrição a qualquer momento. Nunca vendemos seus dados.
Leitura adicional e referências
- Mandiga P, Kommu S, Bollu PC; Hepatic Encephalopathy.
- Sharma K, Akre S, Chakole S, et al; Hepatic Encephalopathy and Treatment Modalities: A Review Article. Cureus. 2022 Aug 14;14(8):e28016. doi: 10.7759/cureus.28016. eCollection 2022 Aug.
- Hepatic encephalopathy: Part 1, a diagnostic approach; Y Ntuli et al; Frontline Gastroenterology
- ACG Clinical Guideline: Hepatic Encephalopathy; J S Bajaj et al; The American Journal of Gastroenterology
- A practical approach to the diagnosis and management of hepatic encephalopathy; N Reau et al; The American Journal of Medicine
- The Management of Hepatic Encephalopathy from Ward to Domiciliary Care: Current Evidence and Gray Areas; D Bellafante et al; Journal of Clinical Medicine
- Hepatic Encephalopathy: Current and Emerging Treatment Modalities; M A Fallahzadeh and R Rahimi; Clinical Gastroenterology and Hepatology
- Cabral CM, Burns DL; Dietas com baixo teor de proteína para encefalopatia hepática desmistificadas: deixem-nos comer bife. Nutr Clin Pract. 2011 Abr;26(2):155-9. doi: 10.1177/0884533611400086.
- Rifaximina para prevenir episódios de encefalopatia hepática manifesta; NICE Technology Appraisal Guidance, March 2015
Sobre o revisorVer biografia completa

Dr Toni Hazell, FRCGP
MBBS, BSc, FRCGP, DFSRH, Dip GU med, DRCOG, DCH (London, UK, 2000)
A Dra. Toni Hazell se formou na Escola de Medicina do Hospital St. Mary e fez seu VTS no Hospital Northwick Park.
Mais em neurologia
- Neurite óptica aguda
- Tumores cerebrais em adultos
- Síndrome da cauda equina
- Distúrbios cerebelares
- Malformações de Chiari
- Visão de cores e seus distúrbios
- Delírios e alucinações
- Tontura, vertigem e sensação de desmaio
- Dislexia
- Encefalite e meningoencefalite
- Lesão do nervo femoral
- Gliomas e glioblastoma multiforme
- Síndrome de Guillain-Barré
- Tumores do nervo óptico e do olho
- Prevenção de quedas em idosos
- Síndrome das pernas inquietas
- Retinoblastoma
- síndrome de Sturge-Weber
- Tratamento trombolítico do acidente vascular cerebral isquêmico agudo
- Incontinência urinária


